Stay updated with breaking news from Control Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HONG KONG, Jan. 8, 2024 /PRNewswire/ -- Akeso, Inc. today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the...
Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2 2024 for Two Randomized...
/PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...
- Luvelta demonstrated encouraging preliminary anti-tumor activity in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate